Abstract

A REVIEW OF NATEGLINIDE IN THE MANAGEMENT OF TYPE 2 DIABETES

Shinde Shraddha B.* and Gondkar Shraddha

Abstract

Nateglinide is oral hypoglycemic agent approved for alone use or in combination with metformin for the treatment of type 2 diabetes mellitus. Nateglinide is amino acid derivative of D- phenylalanine, binds to the ATP potassium channels in pancreatic beta cells and stimulates the secretion of insulin. Approximately one month therapy is required for decrease in fasting blood glucose level. It lowers postprandial blood glucose level and also reduces HbA1c level. Nateglinide is effective at lowering postprandial blood glucose than metformin, sulfonylureas and thiazolidinediones. It is rapidly and completely absorbed in small intestine and has high bioavailability. It is extensively metabolized in liver and excreted in urine and feces.

Keywords: Hypoglycemic agent, diabetes mellitus, nateglinide, metformin, postprandial, HbA1c level.